Metabolic Partnering Agreements -





February 2014 | Pages: 448

The Metabolic Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter metabolic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors metabolic technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

                                

This report contains over 1,000 links to online copies of actual metabolic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of metabolic dealmaking and business activities. Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in metabolic dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

                             

Chapter 3 provides a review of the leading metabolic deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of metabolic deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides comprehensive access to all metabolic deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive directory of all metabolic partnering deals signed and announced since 2009. The chapter is organized by specific metabolic therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided with each report of all metabolic partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in metabolic partnering and dealmaking since 2009.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of metabolic technologies and products.

Executive Summary 

  

Chapter 1 – Introduction 

  

Chapter 2 – Trends in metabolic dealmaking 

 

2.1. Introduction           

2.2. Metabolic partnering over the years           

2.3. Bigpharma metabolic dealmaking activity   

2.4. Bigpharma not active in metabolic  

2.5. Metabolic partnering by deal type   

2.6. Metabolic partnering by industry sector      

2.7. Metabolic partnering by stage of development        

2.8. Metabolic partnering by technology type    

2.9. Metabolic partnering by metabolic indication           

2.10. Average deal terms for metabolic diseases          

2.10.1 Metabolic headline values          

2.10.2 Metabolic upfront payments       

2.10.3 Metabolic milestone payments   

2.10.4 Metabolic royalty rates   

 

Chapter 3 – Leading metabolic deals 

                             

3.1. Introduction           

3.2. Top metabolic deals by value         

3.3. Top metabolic deals involving bigpharma

 

Chapter 4 – Bigpharma metabolic deals 

 

4.1. Introduction

4.2. How to use bigpharma partnering deals      

4.3. Bigpharma metabolic partnering company profiles

Abbott 

Actavis

Allergan           

Amgen

Aspen Pharmacare

Astellas           

AstraZeneca    

Baxter International

Bayer  

Biogen Idec     

Boehringer Ingelheim   

Bristol-Myers Squibb   

Celgene           

Daiichi Sankyo 

Eisai    

Eli Lilly

Endo Pharmaceuticals 

Forest Laboratories      

Gilead Sciences           

GlaxoSmithKline          

Hospira

Johnson & Johnson      

Kyowa Hakko Kirin       

Lundbeck         

Menarini          

Merck & Co     

Merck KGaA    

Merck Serono  

Mitsubishi Tanabe        

Novartis          

Novo Nordisk   

Otsuka

Pfizer  

Pfizer Animal Health     

Pfizer Nutrition 

Roche 

Sanofi  

Servier

Shire   

Takeda

Teva   

Valeant

Watson

 

Chapter 5 – Metabolic partnering contracts directory 

 

5.1. Introduction           

5.2. By deal type          

Asset purchase

Assignment

Bigpharma outlicensing

Co-development           

Collaborative R&D       

Co-market       

Contract service

Co-promotion   

CRADA

Cross-licensing

Development   

Distribution      

Equity purchase           

Licensing         

Litigation         

Loan    

Manufacturing  

Marketing        

Material transfer

Option 

Promotion        

Research         

Royalty financing

Settlement       

Spin out           

Sub-license     

Supply 

Technology transfer

Termination

5.3. By stage of development   

Discovery        

Formulation     

Marketed         

Phase I

Phase II           

Phase III          

Preclinical       

Regulatory       

Formulation     

5.4. By technology type

Analysis          

Animal models 

Assays

Biological compounds  

Biomarkers      

Biomaterials    

Blood products 

Cell culture      

Cell therapy     

Clinical testing

Devices           

Diagnostics     

Discovery tools

Drug delivery   

Enabling technology     

Facilities          

Gene therapy   

Genomics        

Imaging           

Implant

In vitro models 

Nanotechnology           

Natural product

Oligonucleotide

Orphan drug    

Packaging       

Peptides          

Processes       

Proteomics      

Radio/Chemo-therapy  

Recombinant DNA       

Regenerative medicine 

Research services       

Research supplies       

RNA therapeutics         

Screening        

Small molecules          

Stem cells       

Toxicity           

Vaccines

 

Chapter 6 – Metabolic dealmaking by indication 

 

6.1. Introduction           

6.2. Deals by therapeutic indication      

Metabolic         

Acromegaly     

Addison's disease        

Cirrhosis         

Cushing's syndrome    

Diabetes          

Fatty liver        

Gallstones       

Growth hormone disorders

Hyperthyroidism          

Hypogonadism 

Hypothyroidism

Phenylketonuria           

Liver disease   

Lysosomal storage disorders

Nutrition and vitamins

Short stature    

Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

Thyroid disease

 

Chapter 7 – Partnering resource center 

 

7.1. Online partnering   

7.2. Partnering events  

7.3. Further reading on dealmaking

 

About Wildwood Ventures         

Current Partnering       

Current Agreements     

Recent titles from CurrentPartnering     

Order Form – Reports  

Order Form – Therapy Reports

 

Appendices 

 

Appendix 1 – Directory of metabolic deals by company A-Z 2007-2012

Appendix 2 – Directory of metabolic deals by deal type 2007-2012

Appendix 3 – Directory of metabolic deals by stage of development 2007-2012

Appendix 4 – Directory of metabolic deals by technology type 2007-2012

Appendix 5 – Deal type definitions

  

Table of figures 

 

Figure 1: Metabolic partnering since 2009

Figure 2: Bigpharma – top 50 – metabolic deals 2007 to 2012

Figure 3: Bigpharma metabolic deal frequency – 2007 to 2012

Figure 4: Inactive bigpharma in metabolic 2007-2012

Figure 5: Metabolic partnering by deal type since 2009

Figure 6: Metabolic partnering by industry sector since 2009     

Figure 7: Metabolic partnering by stage of development since 2009

Figure 8: Metabolic partnering by technology type since 2009   

Figure 9: Metabolic partnering by metabolic target since 2009   

Figure 10: Metabolic deals with a headline value

Figure 11: Metabolic deal headline value distribution, US$million – discovery stage        

Figure 12: Metabolic deal headline value distribution, US$million – preclinical stage       

Figure 13: Metabolic deal headline value distribution, US$million – phase I stage           

Figure 14: Metabolic deal headline value distribution, US$million – phase II stage          

Figure 15: Metabolic deal headline value distribution, US$million – phase III stage         

Figure 16: Metabolic deal headline value distribution, US$million – regulatory stage       

Figure 17: Metabolic deal headline value distribution, US$million – marketed stage        

Figure 18: Summary median headline value by stage of development, 2007-2012           

Figure 19 Metabolic deals with upfront payment values 

Figure 20: Metabolic deal upfront payment distribution, US$million – discovery stage     

Figure 21: Metabolic deal upfront payment distribution, US$million – preclinical stage    

Figure 22: Metabolic deal upfront payment distribution, US$million – phase I stage        

Figure 23: Metabolic deal upfront payment distribution, US$million – phase II stage       

Figure 24: Metabolic deal upfront payment distribution, US$million – phase III stage      

Figure 25: Metabolic deal upfront payment distribution, US$million – regulatory stage    

Figure 26: Metabolic deal upfront payment distribution, US$million – marketed stage     

Figure 27: Summary median upfront payments by stage of development, 2007-2012      

Figure 28: Metabolic deals with milestone payments     

Figure 29: Metabolic deal milestone distribution, US$million – discovery stage   

Figure 30: Metabolic deal milestone distribution, US$million – preclinical stage

Figure 31: Metabolic deal milestone distribution, US$million – phase I stage      

Figure 32: Metabolic deal milestone distribution, US$million – phase II stage     

Figure 33: Metabolic deal milestone distribution, US$million – phase III stage    

Figure 34: Metabolic deal milestone distribution, US$million – regulatory stage  

Figure 35: Metabolic deal milestone distribution, US$million – marketed stage   

Figure 36: Metabolic deals with royalty rates, %

Figure 37: Metabolic deal royalty rate distribution, US$million – discovery stage

Figure 38: Metabolic deal royalty rate distribution, US$million – preclinical stage

Figure 39: Metabolic deal royalty rate distribution, US$million – phase I stage    

Figure 40: Metabolic deal royalty rate distribution, US$million – phase II stage   

Figure 41: Metabolic deal royalty rate distribution, US$million – phase III stage

Figure 42: Metabolic deal royalty rate distribution, US$million – regulatory stage

Figure 44: Summary median royalty rate by stage of development, 2007-2012

Figure 45: Top metabolic deals by value since 2009

Figure 46: Top metabolic deals signed by bigpharma value since 2009

Figure 47: Online partnering resources 

Figure 48: Forthcoming partnering events